Natural history of hepatitis C - PubMed (original) (raw)
Review
Natural history of hepatitis C
A Alberti et al. J Hepatol. 1999.
Abstract
Ten years after the discovery of the hepatitis C virus (HCV) and its association with NANB hepatitis as a major cause of chronic liver disease worldwide, our knowledge of the natural history of hepatitis C is still limited. The asymptomatic course of the disease in most patients, its slow and silent progression and heterogeneous outcome and the widespread use of interferon therapy during the past decade explain why many questions are still unsolved. The changing epidemiological pattern of HCV and the significant contribution of several cofactors to the severity of liver disease also complicate the development of a general model describing the natural history of hepatitis C. Available data indicate that HCV infection may resolve without any clinical signs of liver disease in individuals exposed to low dose inoculum and that these cases may develop T cell immunity even in the absence of anti-HCV seroconversion. Rates of complete biochemical and virological resolution of acute hepatitis C range between 10 and 50%, and are probably affected by the route of infection, size and type of inoculum and acute phase clinical features. Chronic HCV infection may develop with or without ALT abnormalities and with or without chronic inflammation and increasing fibrosis in the liver. Studies conducted in patients who acquired hepatitis C by blood transfusion 15-25 years ago indicate that 20-30% of them have now progressed to cirrhosis, including 5-10% with end stage liver disease and 4-8% who died of liver-related causes. Similar studies conducted in patients infected by other routes have shown a more benign course of hepatitis C, with little evidence of cirrhosis and no liver-related mortality during the first two decades. Outcomes after longer follow-up need to be assessed. In patients presenting with chronic hepatitis C, fibrosis progression is extremely variable over time and can be partially predicted by the age at infection, disease duration, liver histologic activity and stage of fibrosis and by the ALT profile. However, it is often difficult to predict clinical outcomes in individual cases. In patients who have developed cirrhosis, the 5-year risk of decompensation is between 15 and 20% and that of hepatocellular carcinoma around 10%. Several variables have been shown to influence the natural course of shown C, the most significant being age at infection, alcohol consumption and coinfection with HBV and HIV Studies are being performed to assess the role of host genetics. Viral factors, such as the HCV type and load, seem to have inconsistent or marginal effects.
Similar articles
- Natural history of hepatitis C virus infection: from chronic hepatitis to cirrhosis, to hepatocellular carcinoma.
Leone N, Rizzetto M. Leone N, et al. Minerva Gastroenterol Dietol. 2005 Mar;51(1):31-46. Minerva Gastroenterol Dietol. 2005. PMID: 15756144 English, Italian. - NIH Consensus Statement on Management of Hepatitis C: 2002.
[No authors listed] [No authors listed] NIH Consens State Sci Statements. 2002 Jun 10-12;19(3):1-46. NIH Consens State Sci Statements. 2002. PMID: 14768714 Review. - Coinfection of Schistosoma Species with Hepatitis B or Hepatitis C Viruses.
Abruzzi A, Fried B, Alikhan SB. Abruzzi A, et al. Adv Parasitol. 2016;91:111-231. doi: 10.1016/bs.apar.2015.12.003. Epub 2016 Feb 5. Adv Parasitol. 2016. PMID: 27015949 Review. - Advances in the treatment of hepatitis C.
Lawrence SP. Lawrence SP. Adv Intern Med. 2000;45:65-105. Adv Intern Med. 2000. PMID: 10635046 Review. - Natural history of hepatitis C.
Westbrook RH, Dusheiko G. Westbrook RH, et al. J Hepatol. 2014 Nov;61(1 Suppl):S58-68. doi: 10.1016/j.jhep.2014.07.012. Epub 2014 Nov 3. J Hepatol. 2014. PMID: 25443346 Review.
Cited by
- Plasma levels of methylated septin 9 are capable of detecting hepatocellular carcinoma and hepatic cirrhosis.
He N, Feng G, Zhang C, Wu F, Zhang T, Yang Y. He N, et al. Mol Med Rep. 2020 Oct;22(4):2705-2714. doi: 10.3892/mmr.2020.11356. Epub 2020 Jul 23. Mol Med Rep. 2020. PMID: 32945374 Free PMC article. - Determinants of serum ALT normalization after phlebotomy in patients with chronic hepatitis C infection.
Kawamura Y, Akuta N, Sezaki H, Hosaka T, Someya T, Kobayashi M, Suzuki F, Suzuki Y, Saitoh S, Arase Y, Ikeda K, Kumada H. Kawamura Y, et al. J Gastroenterol. 2005 Sep;40(9):901-6. doi: 10.1007/s00535-005-1636-6. J Gastroenterol. 2005. PMID: 16211347 - Impact of cigarette smoking on response to interferon therapy in chronic hepatitis C Egyptian patients.
El-Zayadi A, Selim O, Hamdy H, El-Tawil A, Badran HM, Attia M, Saeed A. El-Zayadi A, et al. World J Gastroenterol. 2004 Oct 15;10(20):2963-6. doi: 10.3748/wjg.v10.i20.2963. World J Gastroenterol. 2004. PMID: 15378774 Free PMC article. Clinical Trial. - High seroprevalence of HCV in the Abruzzo Region, Italy: results on a large sample from opt-out pre-surgical screening.
Polilli E, Tontodonati M, Flacco ME, Ursini T, Striani P, Di Giammartino D, Paoloni M, Vallarola L, Pressanti GL, Fragassi G, Accorsi P, Manzoli L, Parruti G. Polilli E, et al. Infection. 2016 Feb;44(1):85-91. doi: 10.1007/s15010-015-0841-3. Epub 2015 Sep 12. Infection. 2016. PMID: 26363567 - Chitinase 3-like 1 is a profibrogenic factor overexpressed in the aging liver and in patients with liver cirrhosis.
Nishimura N, De Battista D, McGivern DR, Engle RE, Tice A, Fares-Gusmao R, Kabat J, Pomerenke A, Nguyen H, Sato S, Bock KW, Moore IN, Kleiner DE, Zamboni F, Alter HJ, Govindarajan S, Farci P. Nishimura N, et al. Proc Natl Acad Sci U S A. 2021 Apr 27;118(17):e2019633118. doi: 10.1073/pnas.2019633118. Proc Natl Acad Sci U S A. 2021. PMID: 33888584 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous